Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2019

Open Access 01-12-2019 | Insulins | Case report

Enhancement of postprandial endogenous insulin secretion rather than exogenous insulin injection ameliorated insulin antibody-induced unstable diabetes: a case report

Authors: Keizo Kaneko, Chihiro Satake, Tomohito Izumi, Mamiko Tanaka, Junpei Yamamoto, Yoichiro Asai, Shojiro Sawada, Junta Imai, Tetsuya Yamada, Hideki Katagiri

Published in: BMC Endocrine Disorders | Issue 1/2019

Login to get access

Abstract

Background

Insulin injection, especially with insulin analogs, occasionally induces the production of insulin antibodies with high binding capacity and low affinity, similar to the insulin autoantibodies characteristic of insulin autoimmune syndrome (IAS). Production of these “IAS-like” insulin antibodies causes marked glycemic fluctuations with postprandial hyperglycemia and fasting hypoglycemia.

Case presentation

A 66-year-old man with a 27-year history of diabetes was admitted because of marked glycemic fluctuations. Human insulin treatment had been initiated at age 56, followed by multiple daily injections of insulin analogs 5 years later. After the initial year of insulin analog treatment, the patient began to experience frequent morning hypoglycemic attacks and day-time hyperglycemia. Marked hyperinsulinemia (4500 μU/mL) and high titers of insulin antibodies (80.4%) with high binding capacity and low affinity indicated that IAS-like insulin antibodies were causing severe glucose fluctuations. Altering insulin formulations (insulin aspart → regular human insulin→ insulin lispro) proved to be ineffective. After several therapeutic trials, cessation of exogenous insulin and addition of mitiglinide to liraglutide with voglibose finally attenuated glycemic fluctuations with increased postprandial insulin secretion. Continuous glucose monitoring revealed improvement of morning hypoglycemia and postprandial hyperglycemia with smaller mean amplitude of glycemic excursion. Therefore, compared to exogenously injected insulin, endogenously secreted insulin directly and rapidly acts on hepatocytes and suppresses postprandial glucose output.

Conclusions

Proper enhancement of postprandial endogenous insulin aimed at suppressing postprandial glucose output without stimulating excessive glucose uptake in the periphery is potentially useful for treating diabetes with insulin antibody-induced glycemic instability.
Literature
1.
go back to reference Hirata Y, Uchigata Y. Insulin autoimmune syndrome in Japan. Diabetes Res Clin Pract. 1994;24:S153–7.CrossRef Hirata Y, Uchigata Y. Insulin autoimmune syndrome in Japan. Diabetes Res Clin Pract. 1994;24:S153–7.CrossRef
2.
go back to reference Uchigata Y, Hirata Y. Insulin autoimmune syndrome (IAS, Hirata disease). Ann Med Interne. 1999;150:245–53. Uchigata Y, Hirata Y. Insulin autoimmune syndrome (IAS, Hirata disease). Ann Med Interne. 1999;150:245–53.
3.
go back to reference Fineberg SE, Huang J, Brunelle R, Gulliya KS, Anderson JH Jr. Effect of long-term exposure to insulin lispro on the induction of antibody response in patients with type 1 or type 2 diabetes. Diabetes Care. 2003;26:89–96.CrossRef Fineberg SE, Huang J, Brunelle R, Gulliya KS, Anderson JH Jr. Effect of long-term exposure to insulin lispro on the induction of antibody response in patients with type 1 or type 2 diabetes. Diabetes Care. 2003;26:89–96.CrossRef
4.
go back to reference Ishizuka T, Ogawa S, Mori T, Nako K, Nakamichi T, Oka Y, Ito S. Characteristics of the antibodies of two patients who developed daytime hyperglycemia and morning hypoglycemia because of insulin antibodies. Diabetes Res Clin Pract. 2009;84:e21–3.CrossRef Ishizuka T, Ogawa S, Mori T, Nako K, Nakamichi T, Oka Y, Ito S. Characteristics of the antibodies of two patients who developed daytime hyperglycemia and morning hypoglycemia because of insulin antibodies. Diabetes Res Clin Pract. 2009;84:e21–3.CrossRef
5.
go back to reference Iizuka K, Tomita R, Horikawa Y, Takeda J. A case of glycemic instability and insulin allergy due to anti-insulin antibodies in a patient with type 2 diabetes. Diabetol Int. 2012;3:233–8.CrossRef Iizuka K, Tomita R, Horikawa Y, Takeda J. A case of glycemic instability and insulin allergy due to anti-insulin antibodies in a patient with type 2 diabetes. Diabetol Int. 2012;3:233–8.CrossRef
6.
go back to reference Tamura Y, Kimbara Y, Funatsuki S, Mabuchi S, Remi K, Yoshimoto A, et al. A case of insulin antibody-induced glucose instability in an elderly woman with type 2 diabetes on hemodialysis, successfully ameliorated with liraglutide. Diabetol Int. 2013;4:71–5.CrossRef Tamura Y, Kimbara Y, Funatsuki S, Mabuchi S, Remi K, Yoshimoto A, et al. A case of insulin antibody-induced glucose instability in an elderly woman with type 2 diabetes on hemodialysis, successfully ameliorated with liraglutide. Diabetol Int. 2013;4:71–5.CrossRef
7.
go back to reference Lathela JT, Knip M, Paul R, Antonen J, Salmi J. Severe antibody-mediated human insulin resistance: successful treatment with the insulin analog Lispro. Diabetes Care. 1997;20:71–3.CrossRef Lathela JT, Knip M, Paul R, Antonen J, Salmi J. Severe antibody-mediated human insulin resistance: successful treatment with the insulin analog Lispro. Diabetes Care. 1997;20:71–3.CrossRef
8.
go back to reference Moriyama M, Hayashi N, Ohyabu C, Mukai M, Kawano S, Kumagai S. Performance Evaluation and Cross-reactivity from insulin analogs with the ARCHITECT insulin assay. Clin Chem. 2006;52:1423–6.CrossRef Moriyama M, Hayashi N, Ohyabu C, Mukai M, Kawano S, Kumagai S. Performance Evaluation and Cross-reactivity from insulin analogs with the ARCHITECT insulin assay. Clin Chem. 2006;52:1423–6.CrossRef
9.
go back to reference Uchigata Y, Tokunaga K, Nepom G, Bannai M, Kuwata S, Dozio N, et al. Differential Immunogenetic determinants of polyclonal insulin autoimmune syndrome (Hirata's disease) and monoclonal insulin autoimmune syndrome. Diabetes. 1995;44:1227–32.CrossRef Uchigata Y, Tokunaga K, Nepom G, Bannai M, Kuwata S, Dozio N, et al. Differential Immunogenetic determinants of polyclonal insulin autoimmune syndrome (Hirata's disease) and monoclonal insulin autoimmune syndrome. Diabetes. 1995;44:1227–32.CrossRef
10.
go back to reference Uchigata Y, Hirata Y, Iwamoto Y. Drug-induced insulin autoimmune syndrome. Diabetes Res Clin Pract. 2009;83:e19–20.CrossRef Uchigata Y, Hirata Y, Iwamoto Y. Drug-induced insulin autoimmune syndrome. Diabetes Res Clin Pract. 2009;83:e19–20.CrossRef
11.
go back to reference Yamada T, Imai J, Ishigaki Y, Hinokio Y, Oka Y, Katagiri H. Possible relevance of HLA-DRB1*0403 haplotype in insulin autoimmune syndrome induced by alpha-lipoic acid, used as a dietary supplement. Diabetes Care. 2007;30:e131.CrossRef Yamada T, Imai J, Ishigaki Y, Hinokio Y, Oka Y, Katagiri H. Possible relevance of HLA-DRB1*0403 haplotype in insulin autoimmune syndrome induced by alpha-lipoic acid, used as a dietary supplement. Diabetes Care. 2007;30:e131.CrossRef
12.
go back to reference Buzzetti R, Zampetti S, Maddaloni E. Adult-onset autoimmune diabetes: current knowledge and implications for management. Nat Rev Endocrinol. 2017;13:674–86.CrossRef Buzzetti R, Zampetti S, Maddaloni E. Adult-onset autoimmune diabetes: current knowledge and implications for management. Nat Rev Endocrinol. 2017;13:674–86.CrossRef
13.
go back to reference Song SH, Mcintyre SS, Shah H, Veldhuis JD, Hayes PC, Butler PC. Direct measurement of pulsatile insulin secretion from the portal vein in human subjects. J Clin Endocrinol Metab. 2000;85:4491–9.PubMed Song SH, Mcintyre SS, Shah H, Veldhuis JD, Hayes PC, Butler PC. Direct measurement of pulsatile insulin secretion from the portal vein in human subjects. J Clin Endocrinol Metab. 2000;85:4491–9.PubMed
14.
go back to reference Horwits DL, Starr JI, Mako ME, Blackard WG, Rubenstein AH. Proinsulin, insulin, and C-peptide concentrations in human portal and peripheral blood. J Clin Invest. 1975;55:1278–83.CrossRef Horwits DL, Starr JI, Mako ME, Blackard WG, Rubenstein AH. Proinsulin, insulin, and C-peptide concentrations in human portal and peripheral blood. J Clin Invest. 1975;55:1278–83.CrossRef
15.
go back to reference DeFronzo RA. Pathogenesis of type 2 (non-insulin dependent) diabetes mellitus: a balanced overview. Diabetologia. 1992;35:389–97.CrossRef DeFronzo RA. Pathogenesis of type 2 (non-insulin dependent) diabetes mellitus: a balanced overview. Diabetologia. 1992;35:389–97.CrossRef
16.
go back to reference Rizza RA. Pathogenesis of fasting and postprandial hyperglycemia in type 2 diabetes: implications for therapy. Diabetes. 2010;59:2697–707.CrossRef Rizza RA. Pathogenesis of fasting and postprandial hyperglycemia in type 2 diabetes: implications for therapy. Diabetes. 2010;59:2697–707.CrossRef
17.
go back to reference Moen MF, Zhan M, Hsu VD, Walker LD, Einhorn LM, Seliger SL, et al. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4:1121–7.CrossRef Moen MF, Zhan M, Hsu VD, Walker LD, Einhorn LM, Seliger SL, et al. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4:1121–7.CrossRef
Metadata
Title
Enhancement of postprandial endogenous insulin secretion rather than exogenous insulin injection ameliorated insulin antibody-induced unstable diabetes: a case report
Authors
Keizo Kaneko
Chihiro Satake
Tomohito Izumi
Mamiko Tanaka
Junpei Yamamoto
Yoichiro Asai
Shojiro Sawada
Junta Imai
Tetsuya Yamada
Hideki Katagiri
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2019
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-018-0326-3

Other articles of this Issue 1/2019

BMC Endocrine Disorders 1/2019 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.